Your browser doesn't support javascript.
loading
Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.
Alunno, A; Carubbi, F; Bistoni, O; Caterbi, S; Bartoloni, E; Di Benedetto, P; Cipriani, P; Giacomelli, R; Gerli, R.
Afiliación
  • Alunno A; Rheumatology Section, Department of Medicine, University of Perugia, Perugia, Italy.
  • Carubbi F; Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Bistoni O; Rheumatology Section, Department of Medicine, University of Perugia, Perugia, Italy.
  • Caterbi S; Rheumatology Section, Department of Medicine, University of Perugia, Perugia, Italy.
  • Bartoloni E; Rheumatology Section, Department of Medicine, University of Perugia, Perugia, Italy.
  • Di Benedetto P; Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Cipriani P; Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Giacomelli R; Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Gerli R; Rheumatology Section, Department of Medicine, University of Perugia, Perugia, Italy.
Clin Exp Immunol ; 184(3): 284-92, 2016 Jun.
Article en En | MEDLINE | ID: mdl-26814615
Compelling evidence suggests that interleukin (IL)-17 and IL-17-producing cells play a pivotal role in the pathogenesis of primary Sjögren's syndrome (pSS). We investigated phenotypical and functional effects of the anti-CD20 antibody rituximab (RTX) on circulating and glandular IL-17-producing T cells in pSS. RTX is able to deplete glandular IL-17(+) CD3(+) CD4(-) CD8(-) double-negative (DN) and CD4(+) Th17 cells as well as circulating IL-17(+) DN T cells. A fraction of glandular and circulating IL-17(+) DN cells and CD4(+) T helper type 17 (Th17) cells co-expresses CD20 on the cell surface explaining, at least in part, such depletive capacity of RTX. The exposure to RTX does not rescue the in-vitro corticosteroid resistance of IL-17(+) DN T cells. Our results support further the therapeutic role in pSS of RTX that, despite its B cell specificity, appears able to also hamper IL-17-producing T cells in this disease.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Sjögren / Antígenos CD20 / Interleucina-17 / Células Th17 / Rituximab / Factores Inmunológicos Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: Clin Exp Immunol Año: 2016 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Sjögren / Antígenos CD20 / Interleucina-17 / Células Th17 / Rituximab / Factores Inmunológicos Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: Clin Exp Immunol Año: 2016 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido